Neutrogin - Drug Insights, 2014, New Report Launched

Neutrogin - Drug Insights, 2014 report provides Neutrogin marketed details and API Manufacturers details across the globe along with the location. In addition, it covers sales estimates for the US, detailed clinical assessment of the drug, patent details, route of synthesis, competitive landscape, and analysis of sales performance during the forecast period (2011-2015). The report also includes SWOT analysis for the drug. This report is built using data and information sourced from Publisher proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by Publisher team of industry experts.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Publisher team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Scope

• A review of the Neutrogin based on information derived from company and industry-specific sources
• Coverage of the Marketed data of the Neutrogin on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification
• Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API Manufactures in China & India for Schizophrenia drugs with location details
• Patent Expiry Timeline and Exclusivity Details
• Route of Synthesis of the API
• Global Forecasted Sales Figure from 2011-2015
• Qualitative and quantitative assessment of market space
• SWOT Analysis

Reasons to buy 

• Evaluate the marketing status and exclusivity details of Neutrogin to exploit opportunities for generic drug development opportunities.
• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Neutrogin.
• API intelligence over Neutrogin and gaining primary intelligence over Active Ingredients manufacturers across the globe.
• Understanding the chemical route of synthesis of Neutrogin.
• Uncovering opportunities in the rapidly growing the US market
• Stay ahead of competition by understanding the changing competitive landscape
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
• Obtain sales forecast for currently marketed drug for 2011-2015

Spanning over 35 pages, “Neutrogin - Drug Insights, 2014” report covering the Drug Overview, Global API Manufacturers Assessment, The Pipeline Coverage, Company Profile, Summary, SWOT Analysis, Appendix, Methodology.

Know more about this report at – http://mrr.cm/Zbx

Related Reports:

1st - Combivir-Drug Insights, 2014- visit at: http://mrr.cm/Zbf

2nd - Rocephin-Drug Insights, 2014 - visit at: http://mrr.cm/ZbY

3rd - Halaven-Drug Insights, 2014- visit at: http://mrr.cm/Zbg

To browse more market research reports by Delveinsight visit: http://www.marketresearchreports.com/publisher/delveinsight